Pfizer

News

Pfizer snaps up PD-1/VEGF drug from China's 3SBio

Pfizer has joined the ranks of those developing cancer drugs that target PD-1 and VEGF, penning a $6bn licensing deal with China's 3SBio.

News

EC's von der Leyen loses bid to stop disclosure of Pfizer te...

Ursula von der Leyen has lost a lawsuit attempting to force her to disclose text messages with Pfizer's CEO on COVID-19 vaccine procurement.

News

There's good news for RSV jab firms at delayed ACIP meeting

GSK and Pfizer could see a resurgence in sales of their RSV vaccines if new recommendations at a CDC expert meeting are confirmed by agency leaders.

News

Pfizer's weight-loss aspirations are dealt a heavy blow

Pfizer has been forced to discontinue its oral GLP-1 receptor agonist danuglipron after seeing signs of liver toxicity in late-stage clinical testing.

News

Alnylam joins three-way contest in ATTR cardiomyopathy

Alnylam has claimed FDA approval for Amvuttra in ATTR cardiomyopathy, allowing it to compete with rival therapies from Pfizer and BridgeBio.

News

Pfizer's new drug data in breast cancer draws muted response

Pfizer and Arvinas' much-anticipated oral SERD vepdegestrant for breast cancer missed a key endpoint in its first phase 3 readout.

Pfizer snaps up PD-1/VEGF drug from China's 3SBio

EC's von der Leyen loses bid to stop disclosure of Pfizer te...

There's good news for RSV jab firms at delayed ACIP meeting

Pfizer's weight-loss aspirations are dealt a heavy blow

Alnylam joins three-way contest in ATTR cardiomyopathy

Pfizer's new drug data in breast cancer draws muted response

Europe is facing a surge in STIs, says ECDC

Discover a new era of healthcare panel engagement: Grounded ...

Pfizer

Editor's Picks